Relationship between the posterior atrial wall and the esophagus: esophageal position and temperature measurement during atrial fibrillation ablation (AWESOME-AF). A randomized controlled trial.

Atrial fibrillation Atrial wall thickness Atrioesophageal fistula Catheter ablation Esophageal position

Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 25 05 2022
accepted: 07 07 2022
pubmed: 22 7 2022
medline: 15 12 2022
entrez: 21 7 2022
Statut: ppublish

Résumé

Pulmonary vein isolation (PVI) implies unavoidable ablation lesions to the left atrial posterior wall, which is closely related to the esophagus, leading to several potential complications. This study evaluates the usefulness of the esophageal fingerprint in avoiding temperature rises during paroxysmal atrial fibrillation (PAF) ablation. Isodistance maps of the atrio-esophageal relationship (esophageal fingerprint) were derived from the preprocedural computerized tomography. Patients were randomized (1:1) into two groups: (1) PRINT group, the PVI line was modified according to the esophageal fingerprint; (2) CONTROL group, standard PVI with operator blinded to the fingerprint. The primary endpoint was temperature rise detected by intraluminal esophageal temperature probe monitoring. Ablation settings were as specified on the Ablate BY-LAW study protocol. Sixty consecutive patients referred for paroxysmal AF ablation were randomized (42 (70%) men, mean age 60 ± 11 years). Temperature rise (> 39.1 °C) occurred in 5 (16%) patients in the PRINT group vs. 17 (56%) in the CONTROL group (p < 0.01). Three AF recurrences were documented at a mean follow-up of 12 ± 3 months (one (3%) in the PRINT group and 2 (6.6%) in the CONTROL group, p = 0.4). The esophageal fingerprint allows for a reliable identification of the esophageal position and its use for PVI line deployment results in less frequent esophageal temperature rises when compared to the standard approach. Further studies are needed to evaluate the impact of PVI line modification to avoid esophageal heating on long-term outcomes. The development of new imaging-derived tools could ultimately improve patient safety (NCT04394923).

Sections du résumé

BACKGROUND BACKGROUND
Pulmonary vein isolation (PVI) implies unavoidable ablation lesions to the left atrial posterior wall, which is closely related to the esophagus, leading to several potential complications. This study evaluates the usefulness of the esophageal fingerprint in avoiding temperature rises during paroxysmal atrial fibrillation (PAF) ablation.
METHODS METHODS
Isodistance maps of the atrio-esophageal relationship (esophageal fingerprint) were derived from the preprocedural computerized tomography. Patients were randomized (1:1) into two groups: (1) PRINT group, the PVI line was modified according to the esophageal fingerprint; (2) CONTROL group, standard PVI with operator blinded to the fingerprint. The primary endpoint was temperature rise detected by intraluminal esophageal temperature probe monitoring. Ablation settings were as specified on the Ablate BY-LAW study protocol.
RESULTS RESULTS
Sixty consecutive patients referred for paroxysmal AF ablation were randomized (42 (70%) men, mean age 60 ± 11 years). Temperature rise (> 39.1 °C) occurred in 5 (16%) patients in the PRINT group vs. 17 (56%) in the CONTROL group (p < 0.01). Three AF recurrences were documented at a mean follow-up of 12 ± 3 months (one (3%) in the PRINT group and 2 (6.6%) in the CONTROL group, p = 0.4).
CONCLUSION CONCLUSIONS
The esophageal fingerprint allows for a reliable identification of the esophageal position and its use for PVI line deployment results in less frequent esophageal temperature rises when compared to the standard approach. Further studies are needed to evaluate the impact of PVI line modification to avoid esophageal heating on long-term outcomes. The development of new imaging-derived tools could ultimately improve patient safety (NCT04394923).

Identifiants

pubmed: 35861901
doi: 10.1007/s10840-022-01302-0
pii: 10.1007/s10840-022-01302-0
doi:

Banques de données

ClinicalTrials.gov
['NCT04394923']

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

651-661

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Chew DS, Jones KA, Loring Z, et al. Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization following catheter ablation. Heart Rhythm O2. 2022;3(1):23–31. https://doi.org/10.1016/j.hroo.2021.11.012 .
doi: 10.1016/j.hroo.2021.11.012
Iwasaki Y, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124(20):2264–74. https://doi.org/10.1161/CIRCULATIONAHA.111.019893 .
doi: 10.1161/CIRCULATIONAHA.111.019893
Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–16. https://doi.org/10.1056/NEJMoa2019422 .
doi: 10.1056/NEJMoa2019422
Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. August 2020. https://doi.org/10.1093/eurheartj/ehaa612
Halbfass P, Pavlov B, Muller P, et al. Progression from esophageal thermal asymptomatic lesion to perforation complicating atrial fibrillation ablation: a single-center registry. Circ Arrhythm Electrophysiol. 2017;10(8). https://doi.org/10.1161/CIRCEP.117.005233
Lakkireddy D, Reddy YM, Atkins D, et al. Effect of atrial fibrillation ablation on gastric motility: the atrial fibrillation gut study. Circ Arrhythm Electrophysiol. 2015;8(3):531–6. https://doi.org/10.1161/CIRCEP.114.002508 .
doi: 10.1161/CIRCEP.114.002508
Kadado AJ, Akar JG, Hummel JP. Luminal esophageal temperature monitoring to reduce esophageal thermal injury during catheter ablation for atrial fibrillation: a review. Trends Cardiovasc Med. 2019;29(5):264–71. https://doi.org/10.1016/j.tcm.2018.09.010 .
doi: 10.1016/j.tcm.2018.09.010
Turagam MK, Miller S, Sharma SP, et al. Differences in transient thermal response of commercial esophageal temperature probes: insights from an experimental study. JACC Clin Electrophysiol. 2019;5(11):1280–8. https://doi.org/10.1016/j.jacep.2019.07.013 .
doi: 10.1016/j.jacep.2019.07.013
Schoene K, Arya A, Grashoff F, et al. Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial. Europace. 2020;22(10):1487–94. https://doi.org/10.1093/europace/euaa209 .
doi: 10.1093/europace/euaa209
Grosse Meininghaus D, Blembel K, Waniek C, et al. Temperature monitoring and temperature-driven irrigated radiofrequency energy titration do not prevent thermally induced esophageal lesions in pulmonary vein isolation: a randomized study controlled by esophagoscopy before and after catheter ablation. Heart Rhythm. 2021;18(6):926–34. https://doi.org/10.1016/j.hrthm.2021.02.003 .
doi: 10.1016/j.hrthm.2021.02.003
Kottkamp H, Piorkowski C, Tanner H, et al. Topographic variability of the esophageal left atrial relation influencing ablation lines in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2005;16(2):146–50. https://doi.org/10.1046/j.1540-8167.2005.40604.x .
doi: 10.1046/j.1540-8167.2005.40604.x
Zhang X, Kuang X, Gao X, et al. RESCUE-AF in patients undergoing atrial fibrillation ablation: the RESCUE-AF trial. Circ Arrhythm Electrophysiol. 2019;12(5):e007044. https://doi.org/10.1161/CIRCEP.118.007044 .
doi: 10.1161/CIRCEP.118.007044
Aguinaga L, Palazzo A, Bravo A, et al. Esophageal deviation with vacuum suction and mechanical deflection during ablation of atrial fibrillation: first in man evaluation. J Cardiovasc Electrophysiol. 2021;32(1):67–70. https://doi.org/10.1111/jce.14801 .
doi: 10.1111/jce.14801
Leung LWM, Bajpai A, Zuberi Z, et al. Randomized comparison of oesophageal protection with a temperature control device: results of the IMPACT study. Europace. 2021;23(2):205–15. https://doi.org/10.1093/europace/euaa276 .
doi: 10.1093/europace/euaa276
Teres C, Soto-Iglesias D, Penela D, et al. Personalized paroxysmal atrial fibrillation ablation by tailoring ablation index to the left atrial wall thickness: the “Ablate by-LAW” single-centre study-a pilot study. Europace. 2022;24(3):390–9. https://doi.org/10.1093/europace/euab216 .
doi: 10.1093/europace/euab216
Teres C, Soto-Iglesias D, Penela D, et al. Relationship between the posterior atrial wall and the esophagus: esophageal position during atrial fibrillation ablation. In Press Corrected Proof. Published online: February 13, 2022. https://doi.org/10.1016/j.hroo.2022.02.007
Falasconi G, Penela D, Soto-Iglesias D, et al. A standardized stepwise zero-fluoroscopy approach with transesophageal echocardiography guidance for atrial fibrillation ablation. J Interv Card Electrophysiol. 2021. https://doi.org/10.1007/s10840-021-01086-9 .
doi: 10.1007/s10840-021-01086-9
Teres C, Soto-Iglesias D, Penela D, et al. Left atrial wall thickness of the pulmonary vein reconnection sites during atrial fibrillation redo procedures. Pacing Clin Electrophysiol. 2021;44(5):824–34. https://doi.org/10.1111/pace.14222 .
doi: 10.1111/pace.14222
Ye Y, Chen S-Q, Lu Y-F, et al. PV isolation guided by esophageal visualization with a tailored ablation strategy for the avoidance of esophageal thermal injury: a randomized trial. J Interv Card Electrophysiol an Int J Arrhythm pacing. 2020;58(2):219–27. https://doi.org/10.1007/s10840-019-00572-5 .
doi: 10.1007/s10840-019-00572-5
Parikh V, Swarup V, Hantla J, et al. Feasibility, safety, and efficacy of a novel preshaped nitinol esophageal deviator to successfully deflect the esophagus and ablate left atrium without esophageal temperature rise during atrial fibrillation ablation: the DEFLECT GUT study. Heart Rhythm. 2018;15(9):1321–7. https://doi.org/10.1016/j.hrthm.2018.04.017 .
doi: 10.1016/j.hrthm.2018.04.017
Leung LWM, Akhtar Z, Sheppard MN, Louis-Auguste J, Hayat J, Gallagher MM. Preventing esophageal complications from atrial fibrillation ablation: a review. Heart Rhythm O2. 2021;2(6Part A):651–64. https://doi.org/10.1016/j.hroo.2021.09.004 .
doi: 10.1016/j.hroo.2021.09.004
Carroll BJ, Contreras-Valdes FM, Heist EK, et al. Multi-sensor esophageal temperature probe used during radiofrequency ablation for atrial fibrillation is associated with increased intraluminal temperature detection and increased risk of esophageal injury compared to single-sensor probe. J Cardiovasc Electrophysiol. 2013;24(9):958–64. https://doi.org/10.1111/jce.12180 .
doi: 10.1111/jce.12180
Müller P, Dietrich J-W, Halbfass P, et al. Higher incidence of esophageal lesions after ablation of atrial fibrillation related to the use of esophageal temperature probes. Heart Rhythm. 2015;12(7):1464–9. https://doi.org/10.1016/j.hrthm.2015.04.005 .
doi: 10.1016/j.hrthm.2015.04.005
Sherzer AI, Feigenblum DY, Kulkarini S, et al. Continuous nonfluoroscopic localization of the esophagus during radiofrequency catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18(2):157–60. https://doi.org/10.1111/j.1540-8167.2006.00674.x .
doi: 10.1111/j.1540-8167.2006.00674.x
Hayashi K, Okumura K, Okamatsu H, Kaneko S, Negishi K, Tsurugi T, Tanaka Y, Nakao K, Sakamoto T, Koyama J. Real-time visualization of the esophagus and left atrial posterior wall by intra-left atrial echocardiography. J Interv Card Electrophysiol. 2022;63(3):629–37. https://doi.org/10.1007/s10840-021-01093-w .
doi: 10.1007/s10840-021-01093-w
Nakatani Y, Nuñez-Garcia M, Cheniti G, et al. Preoperative personalization of atrial fibrillation ablation strategy to prevent esophageal injury: impact of changes in esophageal position. J Cardiovasc Electrophysiol. 2022;33(5):908–16. https://doi.org/10.1111/jce.15447 .
doi: 10.1111/jce.15447

Auteurs

Cheryl Teres (C)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.
Lausanne University Hospital, Lausanne, Switzerland.

David Soto-Iglesias (D)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Diego Penela (D)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Giulio Falasconi (G)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Daniel Viveros (D)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Julia Meca-Santamaria (J)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Aldo Bellido (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Jose Alderete (J)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Alfredo Chauca (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Augusto Ordoñez (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Julio Martí-Almor (J)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Claudia Scherer (C)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Alejandro Panaro (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Julio Carballo (J)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Óscar Cámara (Ó)

Department of Information and Communication Technologies, BCN-MedTech, Universitat Pompeu Fabra, PhySense group, Barcelona, Spain.

Jose-Tomás Ortiz-Pérez (JT)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain.

Antonio Berruezo (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12; 08022, Barcelona, Spain. antonio.berruezo@quironsalud.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH